Biopharma Firm Alumis Shares Sink 17% After Downsized IPO
(Bloomberg) -- Shares of Alumis Inc. fell 17% in their trading debut after the clinical stage biopharmaceutical company raised $250 million in a downsized initial public offering with a concurrent private placement.
Most Read from Bloomberg
Justice Department to Charge Boeing, Seeks Guilty Plea from Planemaker
Biden's Defiance Has Democrats Fearing They'll Lose White House
Biden Party Allies Close Ranks as Poll Signals Voter Concern
CLOs Have Too Much Money and Are Running Out of Things to Buy
The company’s shares closed Friday at $13.30 in New York, giving Alumis a market value of about $690 million. Alumis sold about 13.1 million shares Thursday, as well as 2.5 million shares in a concurrent private placement to one of its investors, at $16 each.
Based in the California city of South San Francisco, Alumis focuses on therapies for patients living with immune-mediated diseases who need alternatives to existing treatments, the filing shows. It is developing two Tyrosine Kinase 2 inhibitor product candidates.
The company had a net loss of $155 million in 2023, compared with a net loss of $111.9 million a year earlier, according to the filing.
Alumis had marketed 17.65 million shares for $16 to $18 each. Its largest shareholders before the listing included Foresite Capital Management entities and Baker Brothers Life Sciences LP entities, as well as AyurMaya Capital Management Fund LP, which purchased the private placement shares.
The offering was led by Morgan Stanley, Leerink Partners, Cantor Fitzgerald and Guggenheim Securities. Its shares trade on the Nasdaq Global Market under the symbol ALMS.
(Updates with closing share price in second paragraph)
Most Read from Bloomberg Businessweek
Japan’s Tiny Kei-Trucks Have a Cult Following in the US, and Some States Are Pushing Back
The FBI’s Star Cooperator May Have Been Running New Scams All Along
RTO Mandates Are Killing the Euphoric Work-Life Balance Some Moms Found
How Glossier Turned a Viral Moment for ‘You’ Perfume Into a Lasting Business
©2024 Bloomberg L.P.